Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14848-007US1	Application No. 10/500,499
Information Disclosure Statement by Applicant (Use several sheets if necessary)	Applicant Samuel J. Shuster et al.	
(37 CFR §1.98(b))	Filing Date December 3, 2004	Group Art Unit 1635

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	1.	Allawi et al., "Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase," RNA, 2001, 7(2):314-327
	2.	Ho et al., "Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries," Nat. Biotechnol., 1998, 16:59-63
	3.	Matveeva et al., "A rapid *in vitro* method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures," Nucl. Acids Res., 1997, 25(24):5010-5016
	4.	Matveeva et al., "Prediction of antisense oligonucleotide efficacy by in vitro methods," Nat. Biotechnol., 1998, 16(13):1374-1375
	5.	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," Nat. Biotechnol., 1997, 15(6):537-541
	6.	Patzel et al., "A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability," Nucl. Acids Res., 1999, 27(22):4328-4334
	7.	Patzel and Sczakiel, "Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells," Nat. Biotechnol., 1998, 16(1):64-68
	8.	Walton et al., "Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target," Biotechnol. Bioeng., 1999, 65:1-9

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	